Tired of finishing in last place, Eli Lilly’s new R&D chief wants to shake things up
Bernstein’s Tim Anderson has been holding some in-depth discussions with the executive team at Eli Lilly, including Dan Skovronsky, the incoming head of R&D. And it’s clear that Skovronsky — who’s taking Jan Lundberg’s place June 1 — intends to get more aggressive in early-stage development as he works to completely shed a well-earned reputation for a go-slow clinical approach that has frequently put them at the end of a long line of rivals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.